Business
Cerus Corporation Announces First Quarter 2025 Financial Results
First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million
About this update from Cerus Corporation
[{"type":"text","content":"\nFirst quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year\n\nReiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million\n\nFirst Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million\n\nConference Call Today at 4:30 pm ET\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update.\n\n“We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus’ mission to transform the safety and availability of transfused blood components,” said William “Obi” Greenman, Cerus’ president and chief executive officer. “We delivered 13% first quarter product revenue growth, in-line with our Q1 guidance, received CE Mark for the INT200, our next generation LED-based illumination device ahead of plan, and most recently, we have submitted our updated CE Mark application for the INTERCEPT red blood cell system to TÜV-SÜD, our notified body.”\n\n“Based on revenue growth prospects for 2025 and beyond, our expected gross margin profile, and demonstrated financial discipline, we believe we are in a position to deliver operating cash flow to fuel our growth and make INTERCEPT the standard of care for blood safety globally,” continued Greenman.\n\nAdditional highlights include:\n\n\nFirst-quarter 2025 total revenue was comprised of (in millions, except percentages):\n\n\n\n\nThree Months Ended\n\n\n\n\n\n\n\n\nMarch 31,\n\n\n\n \n\n\n\nChange\n\n\n\n\n\n\n2025\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n$\n\n\n\n \n\n\n\n%\n\n\n\n\nProduct Revenue\n\n$\n\n\n\n43.2\n\n\n\n\n$\n\n\n\n38.4\n\n\n\n\n$\n\n\n\n4.9\n\n\n\n\n13\n\n\n\n%\n\n\n\n\nGovernment Contract Revenue\n\n \n\n\n\n5.6\n\n\n\n\n \n\n\n\n5.0\n\n\n\n\n \n\n\n\n0.6\n\n\n\n\n12\n\n\n\n%\n\n\n\n\nTotal Revenue\n\n$\n\n\n\n48.9\n\n\n\n\n$\n\n\n\n43.4\n\n\n\n\n$\n\n\n\n5.5\n\n\n\n\n13\n\n\n\n%\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nNumbers may not sum due to rounding. Percentages are based on actuals.\n\n\n\n\n\nAdoption of INTERCEPT Fibrinogen Complex (IFC) continues to increase; first quarter 2025 IFC revenue of $3.0 million compared to $1.9 million in the prior year period. The Company continues to collaborate with blood bank partners to increase I...